🇧🇷Brazil
Medicare Fraud Risk from Unbilled Parallel MTM Services
1 verified sources
Definition
Pharmacies providing MTM services outside contracted platforms without billing Medicare expose themselves to fraud accusations if parallel services are not charged. Platforms like OutcomesMTM require exclusive billing, and additional services must be documented or risk compliance violations. This creates revenue loss alongside heightened audit scrutiny in Medicare/Medicaid MTM programs.
Key Findings
- Financial Impact: Full service value plus fraud penalties/repayments
- Frequency: Ongoing per uncontracted MTM delivery - systemic platform dependency
- Root Cause: Exclusive MTM platform contracts prohibiting direct pharmacy billing
Why This Matters
This pain point represents a significant opportunity for B2B solutions targeting Retail Pharmacies.
Affected Stakeholders
MTM coordinators, pharmacy compliance officers, contract managers
Action Plan
Run AI-powered research on this problem. Each action generates a detailed report with sources.
Methodology & Sources
Data collected via OSINT from regulatory filings, industry audits, and verified case studies.
Related Business Risks
Incorrect MTM Billing Codes Leading to Zero Reimbursement
$34-$130 per unbilled unit (based on service level rates)
Overcharging MTM Services Beyond State-Regulated Amounts
Refunds plus potential fines under Wis. Stat. § 49.688(5)(a)
Denied MTM Claims Due to New vs Established Patient Coding Errors
$52-$148 per denied CMR/A service
HRSA Audit Failures and Required Repayments for Diversion/Duplicate Discounts
$Repayment of full discounts plus potential civil monetary penalties per audit
Excess Labor and Overtime from Manual Compliance and Documentation Tasks
$1,000–$6,000 per store per month in additional labor and overtime associated with controlled‑substance record‑keeping and reconciliation
Delayed Reimbursement from Holds and Rejections on Controlled Substance Claims
$500–$4,000 per store per month in financing cost of delayed cash and staff time for claims follow‑up related to controlled substances